NASDAQ:VRCA

Verrica Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy VRCA

*Your capital is at risk

$5.87

+0.0800 (+1.38%)

At Close: Jun 03, 2026

Verrica Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.99. In total, the insiders bought 119.72M and sold 908.63K VRCA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.99
● Buy	119.72M shares
● Sell	908.63K shares
96% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Jun 01, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.99. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (96% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 26, 2025 Buy	Common Stock J-Other	Frantzreb Charles	Director	0 Value: $0
Dec 26, 2025 Buy	Common Stock, par value $0.0001 per share ("Common Stock")	Caligan Partners Lp See Remarks	Other	0 Value: $0
Dec 23, 2025 Buy	Common Stock A-Award	Kirby John J. Interim CFO	C-Suite Officer	10 000 Value: $82.1K
Nov 25, 2025 Buy	Series B Warrants (right to buy)	Bkb Growth Investments, Llc 10 Percent Owner	10% Owner	224 719 Value: $3.00M
Nov 25, 2025 Buy	Series C Warrants (right to buy)	Bkb Growth Investments, Llc 10 Percent Owner	10% Owner	687 690 Value: $4.34M
Nov 25, 2025 Buy	Common Stock	Bkb Growth Investments, Llc 10 Percent Owner	10% Owner	0 Value: $0
Nov 25, 2025 Buy	Series B Warrants (right to buy)	Bkb Growth Investments, Llc 10 Percent Owner	10% Owner	224 719 Value: $300.0K
Nov 25, 2025 Buy	Pre-Funded Warrants (right to buy)	Caligan Partners Lp See Remarks	Other	4 126 239 Value: $413
Nov 25, 2025 Buy	Series C Warrants (right to buy)	Caligan Partners Lp See Remarks	Other	1 031 559 Value: $6.51M
Nov 25, 2025 Buy	Common Stock P-Purchase	Manning Paul B	Director	1 375 380 Value: $5.84M
Nov 25, 2025 Buy	Series C Warrant (right to buy) P-Purchase	Rieger Jayson CEO And President	CEO / President	23 577 Value: $148.9K
Nov 25, 2025 Buy	Common Stock P-Purchase	Rieger Jayson CEO And President	CEO / President	94 311 Value: $400.1K
Nov 25, 2025 Buy	Series C Warrant (right to buy) P-Purchase	Zawitz David Chief Operating Officer	C-Suite Officer	2 500 Value: $15.8K
Nov 25, 2025 Buy	Common Stock P-Purchase	Zawitz David Chief Operating Officer	C-Suite Officer	10 000 Value: $42.4K
Nov 25, 2025 Buy	Series C Warrant (right to buy) P-Purchase	Kirby John J. Interim CFO	C-Suite Officer	884 Value: $6K
Nov 25, 2025 Buy	Common Stock P-Purchase	Kirby John J. Interim CFO	C-Suite Officer	3 536 Value: $15.0K
Nov 25, 2025 Buy	Series C Warrant (right to buy) P-Purchase	Rosenberg Noah L. Cmo	Officer	589 Value: $4K
Nov 25, 2025 Buy	Common Stock P-Purchase	Rosenberg Noah L. Cmo	Officer	2 357 Value: $10K
Nov 25, 2025 Buy	Common Stock P-Purchase	Manning Paul B	Director	2 750 762 Value: $11.7M
Nov 25, 2025 Buy	Series C Warrant (right to buy) P-Purchase	Manning Paul B	Director	343 845 Value: $2.17M
Nov 25, 2025 Buy	Series C Warrant (right to buy) P-Purchase	Manning Paul B	Director	687 690 Value: $4.34M
Jun 05, 2025 Buy	Stock Option (right to buy) A-Award	Corcoran Gavin Director	Director	20 000 Value: $11.6K
Jun 05, 2025 Buy	Stock Option (right to buy) A-Award	Nguyen Diem Director	Director	20 000 Value: $11.6K
Jun 05, 2025 Buy	Stock Option (right to buy) A-Award	Eichenfield Lawrence Director	Director	20 000 Value: $11.6K
Jun 05, 2025 Buy	Stock Option (right to buy) A-Award	Prygocki Mark A Sr Director	Director	20 000 Value: $11.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT VERRICA PHARMACEUTICALS INC

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based p...

Read Full Profile Here